BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Angiogenesis
,
Obesity
,
Heart
,
Alcohol
,
Fluoxetine
,
rs3825942
,
CYP51
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ro 28-2653
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
Selective MMP-inhibition with Ro 28-2653 in acute experimental stroke--a magnetic resonance imaging …
Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with …
Radiofluorinated pyrimidine-2,4,6-triones as molecular probes for noninvasive MMP-targeted imaging.
The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in tr…
Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and M…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab…
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV D…
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel A…
Dental Implants in Patients Under Oral Anticoagulant Therapy
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ